Literature DB >> 18587690

Epidemiology of pulmonary hypertension: new data from the Swiss registry.

Claudia Tueller1, Hans Stricker, Paola Soccal, Michael Tamm, John-David Aubert, Marco Maggiorini, Marcel Zwahlen, Laurent Nicod.   

Abstract

BACKGROUND: since 1999 data from pulmonary hypertension (PH) patients from all PH centres in Switzerland were prospectively collected. We analyse the epidemiological aspects of these data.
METHODS: PH was defined as a mean pulmonary artery pressure of >25 mm Hg at rest or >30 mm Hg during exercise. Patients with pulmonary arterial hypertension (PAH), PH associated with lung diseases, PH due to chronic thrombotic and/or embolic disease (CTEPH), or PH due to miscellaneous disorders were registered. Data from adult patients included between January 1999 and December 2004 were analysed.
RESULTS: 250 patients were registered (age 58 +/- 16 years, 104 (41%) males). 152 patients (61%) had PAH, 73 (29%) had CTEPH and 18 (7%) had PH associated with lung disease. Patients <50 years (32%) were more likely to have PAH than patients >50 years (76% vs. 53%, p <0.005). Twenty-four patients (10%) were lost to followup, 58 patients (26%) died and 150 (66%) survived without transplantation or thrombendarterectomy. Survivors differed from patients who died in the baseline six-minute walking distance (400 m [300-459] vs. 273 m [174-415]), the functional impairment (NYHA class III/IV 86% vs. 98%), mixed venous saturation (63% [57-68] vs. 56% [50-61]) and right atrial pressure (7 mm Hg [4-11] vs. 11 mm Hg [4-18]). DISCUSSION: PH is a disease affecting adults of all ages. The management of these patients in specialised centres guarantees a high quality of care. Analysis of the registry data could be an instrument for quality control and might help identify weak points in assessment and treatment of these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18587690     DOI: 2008/25/smw-11915

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  18 in total

Review 1.  Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Dike B Ojji; Andre Pascal Kengne; Ana Olga Mocumbi; Karen Sliwa; Friedrich Thienemann
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

2.  Hemoptysis requiring bronchial artery embolization in pulmonary arterial hypertension.

Authors:  Jose A Cantu; Zeenat Safdar
Journal:  South Med J       Date:  2010-09       Impact factor: 0.954

3.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

4.  Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.

Authors:  Lynette M Brown; Hubert Chen; Scott Halpern; Darren Taichman; Michael D McGoon; Harrison W Farber; Adaani E Frost; Theodore G Liou; Michelle Turner; Kathy Feldkircher; Dave P Miller; C Gregory Elliott
Journal:  Chest       Date:  2011-03-10       Impact factor: 9.410

5.  Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.

Authors:  Paula Appenzeller; Mona Lichtblau; Charlotte Berlier; John-David Aubert; Andrea Azzola; Jean-Marc Fellrath; Thomas Geiser; Frederic Lador; Susanne Pohle; Isabelle Opitz; Markus Schwerzmann; Hans Stricker; Michael Tamm; Stéphanie Saxer; Silvia Ulrich
Journal:  Pulm Circ       Date:  2022-01-05       Impact factor: 2.886

6.  Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study.

Authors:  Yonghua Chen; Chunli Liu; Wenju Lu; Mengxi Li; Cyrus Hadadi; Elizabeth Wenqian Wang; Kai Yang; Ning Lai; Junyi Huang; Shiyue Li; Nanshan Zhong; Nuofu Zhang; Jian Wang
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

7.  Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study.

Authors:  Geoff Strange; Eli Gabbay; Fiona Kermeen; Trevor Williams; Melinda Carrington; Simon Stewart; Anne Keogh
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

Review 8.  Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature.

Authors:  Xiaoqin Yang; Jack Mardekian; Kafi N Sanders; Marko A Mychaskiw; Joseph Thomas
Journal:  Clin Rheumatol       Date:  2013-06-20       Impact factor: 2.980

9.  Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry.

Authors:  Pavel Jansa; Jiri Jarkovsky; Hikmet Al-Hiti; Jana Popelova; David Ambroz; Tomas Zatocil; Regina Votavova; Pavel Polacek; Jana Maresova; Michael Aschermann; Petr Brabec; Ladislav Dusek; Ales Linhart
Journal:  BMC Pulm Med       Date:  2014-03-15       Impact factor: 3.317

10.  Pulmonary hypertension in Portugal: first data from a nationwide registry.

Authors:  Rui Baptista; José Meireles; Ana Agapito; Graça Castro; António Marinho da Silva; Teresa Shiang; Fabienne Gonçalves; Susana Robalo-Martins; António Nunes-Diogo; Abílio Reis
Journal:  Biomed Res Int       Date:  2013-10-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.